This is the downside of publicly-funded labs selling patent-licensing rights to private companies:
Given the urgency, it’s inexplicable that one of the candidate vaccines, developed at the Public Health Agency of Canada (PHAC) in Winnipeg, has yet to go in the first volunteer’s arm, says virologist Heinz Feldmann, who helped develop the vaccine while at PHAC. “It’s a farce; these doses are lying around there while people are dying in Africa,” says Feldmann, who now works at the Rocky Mountain Laboratories of the U.S. National Institute of Allergy and Infectious Diseases (NIAID) in Hamilton, Montana. At the center of the controversy is NewLink Genetics, a small company in Ames, Iowa, that bought a license to the vaccine’s commercialization from the Canadian government in 2010, and is now suddenly caught up in what WHO calls “the most severe acute public health emergency seen in modern times.” Becker and others say the company has been dragging its feet the past 2 months because it is worried about losing control over the development of the vaccine.
“A command-line power tool for Twitter.” It really is — much better timeline searchability than the “real” Twitter UI, for example
We’ve had almost 40 years to develop, test and stockpile an Ebola vaccine. That has not happened because big pharma has been entirely focused on shareholder value and profits over safety and survival from a deadly virus. For the better part of Ebola’s 38 years ? big pharma has been asleep. The question ahead is what virus or superbug will wake them up?
Links for 2014-10-04
permalink. Both comments and trackbacks are currently closed.. Bookmark the